Xiangxue Pharma’s XLS-103 Wins NMPA Clinical Trial Approval for KRAS G12V–Positive Advanced Colorectal Cancer – Proprietary TCR-T Cell Therapy Expands to Third Tumor Type in China
Guangzhou Xiangxue Pharmaceutical Co., Ltd ("XPH") (SHE: 300147) announced that its investigational TCR-T cell therapy candidate XLS-103 has received clinical trial approval from China's National Medical Products Administration (NMPA) for…
Empowering Chinese Pharma’s Global Expansion
Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
